Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes

Cohort 1: Multi-omics study in early-stage synchronous multiple primary lung cancer

Inclusion criteria

• Male or female patients:18-75 years old;
• ECOG score:0-1;
• Histopathologically confirmed TNM stage I-II NSCLC;
• Considered multiple or solitary primary lung cancer by clinical criteria (Martini-Melamed criteria and ACCP criteria);
• Good compliance, family members agree to cooperate to receive survival follow-up;
• Understand and voluntarily sign the informed consent.

Exclusion criteria

• A history of previous or co-existing malignant tumors;
• Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
• Refusal to participate in the study.

Cohort 2: Multi-omics study of lung cancer associated with cystic airspaces

Inclusion criteria

• Male or female patients:18-75 years old;
• ECOG score:0-1;
• Histopathologically confirmed TNM stage I-II NSCLC;
• CT findings show solitary or multiple nodules with cystic airspaces.

Exclusion criteria

• A history of previous or co-existing malignant tumors;
• Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
• Refusal to participate in the study.